BRIEF-Camurus Announces FDA Acceptance Of NDA Resubmission For Oclaiz

Cambiar Aggressive Value ETF

Cambiar Aggressive Value ETF

CAMX

0.00

Jan 9 (Reuters) - Camurus AB CAMX.ST:

  • CAMURUS ANNOUNCES FDA ACCEPTANCE OF NDA RESUBMISSION FOR OCLAIZ™ FOR THE TREATMENT OF ACROMEGALY

  • CAMURUS AB - PDUFA TARGET ACTION DATE SET FOR 10 JUNE 2026

  • CAMURUS AB: PRODUCT RECEIVED MARKETING AUTHORIZATION IN THE EU AND UK IN 2025 UNDER THE PRODUCT NAME OCZYESA, PRODUCT LAUNCH INITIATED IN THE EU

Source text: ID:nPnb3TGq7a

Further company coverage: CAMX.ST


((Reuters.Briefs@thomsonreuters.com;;))

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.